🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  2. Radiotherapy plus temozolomide

    The First People's Hospital of Lianyungang

    Glioma (Any Grade) in the Brain

    phase 2 small molecule active

    1 trial

  3. Radium-223 dichloride (Xofigo, BAY88-8223)

    Bayer HealthCare AG

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  4. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  5. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  6. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  7. Ritlecitinib Tosilate, Placebo for pf-06651600-15

    Pfizer Australia Pty Ltd

    HIDRADENITIS SUPPURATIVA

    phase 2 small molecule active

    1 trial

  8. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  9. SAR442970

    Sanofi Pasteur

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  10. SAR444656 (KT-474)

    Kymera Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule terminated

    1 trial

  11. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  12. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

  13. SODIUM CHLORIDE, ADALIMUMAB, LAD191, LAD191 placebo

    Almirall, S.A.

    Moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  14. SODIUM CHLORIDE, ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  15. SR419

    Shanghai University of Traditional Chinese Medicine

    Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  16. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  17. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Prader-Willi Syndrome

    phase 2 small molecule active

    2 trials

  18. Sintilimab in combination with Multimodality Radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  19. Sodio cloruro S.A.L.F. 0,9% solvente per uso parenterale., BCG 10 Anti-Tuberculosis Vaccine, Powder and solvent for suspension for intradermal injection Vaccinum tuberculosis (BCG) cryodesiccatum

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  20. Sonelokimab (M1095)

    MoonLake Immunotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  21. Spermidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Xerostomia

    phase 2 small molecule active

    1 trial

  22. Spray of spirulina derivatives

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Oral Mucositis

    phase 2 small molecule active

    1 trial

  23. Stivarga 40 mg film-coated tablets

    Istituto Gentili S.r.l.

    grade 1, 2 and 3 meningioma

    phase 2 small molecule active

    1 trial

  24. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources